By analyzing the adrenocortical carcinoma dataset in the cancer genome atlas (TCGA), a study found that the increased expression of cyclin-dependent kinase-1 (CDK1) is significantly associated with the adverse clinical outcomes of adrenocortical carcinoma. This evidence concerns the gene CDK1 and cancer.